{"Clinical Trial ID": "NCT00454532", "Intervention": ["INTERVENTION 1:", "Level 1", "10 g/day", "INTERVENTION 2:", "Level 2", "20 g/day"], "Eligibility": ["Key Inclusion Criteria:", "Women 18 years of age or older", "- Breast cancer confirmed histologically", "Clinical evidence of metastatic metastases (stage IV) (other than bone metastases)", "Availability of estrogen and progesterone receptor status", "At least one measurable disease site defined by the RECIST criteria, 30 days prior to treatment under study", "For Phase 1, no more than 3 previous cytotoxic schemes for metastatic breast cancer. For Phase 2, no more than 2 previous cytotoxic schemes for metastatic breast cancer", "Life expectancy 12 weeks", "Performance Status of the Eastern Cooperative Oncology Group 2", "Women of childbearing potential must accept two forms of contraception during the trial.", "Key Exclusion Criteria:", "Unable to understand or agree to sign informed written consent", "Any significant adverse reaction related to chemo, radiotherapy, biology or prior hormone therapy that has not been resolved according to the investigator's judgement", "The current use of a research officer", "Clinically significant gastrointestinal anomalies", "Currently, use of coumadine at therapeutic doses or within 2 weeks of taking drugs under study", "\u2022 Concomitant treatment of radiation or palliative anticancers", "Women who report pregnancy, breast-feeding or have a positive pregnancy test"], "Results": ["Performance measures:", "Version 3 (Phase 1)", "Dose-Limiting Toxicities classified according to common terminology criteria for adverse events, version 3.0", "Time limit: Monthly", "Results 1:", "Title of arm/group: Level 1", "Description of the arm/group: 10g/day", "Total number of participants analysed: 11", "Type of measurement: Number", "Unit of measurement: High ASAT participants: 1", "Diarrhoea: 0", "Fatigue: 0", "Cage with veins of pain: 0", "Results 2:", "Title of arm/group: Level 2", "Description of the arm/group: 20g/day", "Total number of participants analysed: 6", "Type of measurement: Number", "Unit of measurement: High ASAT participants: 0", "Diarrhoea: 1", "Fatigue: 1", "Cage with veins of pain: 0"], "Adverse Events": ["Undesirable Events 1:", "Total: 5/11 (45.45 per cent)", "Haemorrhage, GI- abdomen NOS 21/11 (9.09%)", "21/11 (9.09%)", "Infection-ulceration 20/11 (0.00 %)", "Hemoglobin 20/11 (0.00 %)", "Hypoglycaemia 20/11 (0.00 %)", "Cage of veins due to vomiting 20/11 (0.00 %)", "Obstruction-gu ureter 1/11 (9.09 %)", "- Vesicular haemorrhage 21/11 (9.09%)", "Breast pain 21/11 (9.09%)", "22/11 (18.18 per cent)", "Adverse Events 2:", "Total: 0/6 (0.00 per cent)", "Hemorrhage, GI- abdomen NOS 20/6 (0.00 %)", "- Feeling pain 20/6 (0.00 %)", "Infection-ulceration 20/6 (0.00 %)", "Hemoglobin 20/6 (0.00 %)", "Hypoglycaemia 20/6 (0.00 %)", "Cage of veins due to vomiting 20/6 (0.00 %)", "0/6 (0.00 %)", "\u00b7 Vesicular haemorrhage 20/6 (0.00 %)", "Breast pain 20/6 (0.00 %)", "20/6 (0.00 %)"]}